Checkpoint Therapeutics (CKPT)
(Delayed Data from NSDQ)
$1.50 USD
-0.06 (-3.85%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.49 -0.01 (-0.67%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Checkpoint Therapeutics, Inc. [CKPT]
Reports for Purchase
Showing records 41 - 47 ( 47 total )
Company: Checkpoint Therapeutics, Inc.
Industry: Unclassified
Brighter Spotlight on CK-101 Soon; Oral Late-Breaker at World Lung Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Unclassified
2Q18 Results; Time Is Upon Us Shortly for Data to Drive Pivotal Plans Next Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Unclassified
1Q18 Results; Looking for Quick Transition to Pivotal Phase for CK-301
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Unclassified
CK-301 Expansion Cohort Dosing Underway; On Track Towards Pivotal Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Unclassified
2017 Results; Don''t Forget, De-Risked Pivotal Start Not Too Far Off; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Unclassified
The CK-301 Plan Is Coming Together Quickly; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Unclassified
Derisked Strategy and Rapid Progress Toward Pivotal Stage; Initiating Coverage at Buy and $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J